Hoth Therapeutics stock (US44133K1097): biotech pivots toward AI chips with Rocket One plan

Hoth Therapeutics plans a bold strategic shift: a Rocket One rebrand and pivot from early?stage biotech toward AI accelerator chips. What this could mean for the Nasdaq-listed micro cap and for US investors following AI hardware and speculative healthcare plays.

Hoth Therapeutics, a clinical-stage biopharma focused on inflammatory and dermatologic diseases, has announced plans to change its name to Rocket One and pivot its main business toward artificial intelligence accelerator chips, according to an April 2025 report on the strategy shift that cites company communications and regulatory filingsEngineering.com as of 04/15/2025.

As of: 21.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Hoth Therapeutics
• Sector/industry: Biotechnology / emerging AI hardware
• Core markets: United States research and healthcare partners
• Key revenue drivers: R&D partnerships and future product commercialization
• Home exchange/listing venue: Nasdaq (ticker: HOTH)
• Trading currency: USD

Hoth Therapeutics: core business model

Hoth Therapeutics has historically positioned itself as a development-stage biotechnology company working on treatments for dermatologic and inflammatory indications, using in-licensed and proprietary assets aimed at improving patient quality of life, as described on its corporate homepageHoth Therapeutics website as of 03/10/2025.

The company’s pipeline has included preclinical and early-clinical programs that target conditions such as atopic dermatitis and other inflammatory skin diseases, with a strategy centered on collaborating with academic institutions and specialized contract research organizations in the US and abroadHoth Therapeutics website as of 03/10/2025.

As a micro-cap listed on Nasdaq, Hoth Therapeutics has typically relied on equity financing to fund research activities, a common pattern in early-stage biotech where revenue from product sales is not yet available and milestones depend on clinical progress and licensing opportunities.

Main revenue and product drivers for Hoth Therapeutics

Hoth Therapeutics does not yet generate significant product revenue and instead focuses on building asset value through research milestones, intellectual property, and potential out-licensing deals with larger pharmaceutical partners that may co-fund or acquire promising candidates at later clinical stagesHoth Therapeutics investor materials as of 02/28/2025.

The company’s economics are therefore tied to clinical trial outcomes, regulatory feedback, and the ability to secure grants or collaborations, which can provide non-dilutive capital but are often highly competitive and subject to scientific and regulatory uncertaintyHoth Therapeutics investor materials as of 02/28/2025.

Because its drug candidates are still in early stages, operational spending on research, development, and general corporate expenses tends to outweigh any incoming cash, meaning further capital raises on US equity markets may remain an important funding tool as the company pursues both biotech assets and its planned AI chip activities.

Conclusion

Hoth Therapeutics remains a high-risk, development-stage Nasdaq listing whose value depends on clinical execution and the success of its planned pivot toward AI accelerator chips under the future Rocket One name. US investors following speculative biotech and AI hardware themes may view the combination as an unusual hybrid story, but the lack of mature revenue streams and the complexity of operating in two demanding industries underline the importance of close attention to future filings, financing steps, and strategic updates.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.